Skip to content

Radiopharmaceutical stability, re-engineered

DuraRad is built so more doses reach more patients, in more places.

DuraRad is a sol-gel enzyme coating on the inside of the vial wall. It acts as a sink for the reactive oxygen species radiolysis creates, keeping their concentration low so radiochemical purity holds longer.

  • Cold-bench peroxide clearance: k = 0.107 min⁻¹
  • No enzyme leaching detected in bench challenge testing
  • Live-decay validation scheduled for Q4 2026
Request the data package Start a partnership conversation
An empty DuraRad 6R serum vial with an aluminum crimp seal and white flip-off cap on a neutral gray surface.

The decay picture

Watch a dose hold its purity.

This is the shape of the problem and the shape of the fix: an unprotected dose loses radiochemical purity to its own decay and crosses the release spec early, while a DuraRad-coated dose holds above it longer. The interactive model runs the radiolysis math, isotope by isotope.

See the interactive model
Radiochemical purity over storage time An illustrative schematic. An unprotected drug product loses radiochemical purity steeply and crosses the release specification early. A DuraRad-protected product holds above the release specification across the whole window shown. The shaded band between the two curves is the recovered usable reach. Not measured data. t = 0 storage time → radiochemical purity DuraRad Unprotected release spec out of spec

Scroll the chart

Illustrative. Radiochemical purity over storage time — not measured data.

Explore DuraRad

From the problem to the proof.

Isotope decay sets the clock; radiolysis moves it up. DuraRad puts an active enzyme sink in the vial wall to give some of that time back. The whole case, from the physics to the plan that proves it, is laid out in the order the story unfolds. Start anywhere.

01

The problem

Radioligand therapy is one of oncology's fastest-growing modalities, and every dose races its own half-life. Radiolysis makes that race harder, so doses expire before they reach the patient.

See the stakes 02

The technology

A sol-gel enzyme coating on the vial wall that consumes the reactive oxygen species radiolysis generates, slowing the loss of radiochemical purity through storage.

See the mechanism 03

The model

An interactive, physics-grounded simulator: watch peroxide build in an uncoated vial and a DuraRad-coated vial draw it down, with real numbers.

Open the model 04

The isotopes

Ten clinical isotopes, each with its own radiolysis fingerprint, from the Lu-177 workhorse to the high-LET alpha emitters.

Explore the physics 05

The evidence

Three measured cold-bench results, set against every modeled projection: a diligence-grade view of where DuraRad stands today.

Review the evidence 06

The validation

The Q4 2026 radioactive study designed to carry DuraRad's measured cold-bench clearance into measured in-vial performance under live decay, built around two of the field's toughest isotopes.

Follow the milestone 07

The company

FabUTech LLC, founded by a radiopharma leader who contributed to three FDA-approved biologics and led CMC on a Zr-89-radiolabeled monoclonal antibody BLA: the team and the mission behind DuraRad.

Meet the company 08

The evaluation kit

DuraRad-coated vials for your own bench evaluation, no radioactive material shipped. Reserve a kit as the program scales.

Reserve a kit

The reach

Every hour of shelf life is more reach.

Every hour a dose keeps its purity is an hour it can still travel. Time lost to radiolysis shrinks the circle of clinics a single production run can reach, and strands more doses past expiry before they arrive.

Hold radiochemical purity longer and that circle widens: the same batch, made in the same place, reaches farther, so more doses are used and more patients treated, in more places.

Reach, drawn on a world map A conceptual animation on a dotted world map. From a single production site in the central United States, unnamed clinic locations light up in waves: nearby ones first, then — as the frame widens to the whole map — cities across continents. Illustrative only — not modeled distances or patient numbers.
  • Production
  • Reach today
  • Reach with DuraRad
Illustrative. A conceptual view of reach — not modeled distances or patient numbers.

Get in touch

Let's talk stability.

The single next step is the DuraRad data package: a concise technical summary for partnership, investment, and validation conversations.

Request the data package